![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
Sponsored by: |
Hospital Clinic of Barcelona |
---|---|
Information provided by: | Hospital Clinic of Barcelona |
ClinicalTrials.gov Identifier: | NCT00298714 |
There is evidence on the beneficial effects of the administration of angiotensin II type 1 (AT1) receptors antagonists on liver fibrosis in hepatic stellate cells, experimental models of liver fibrosis in rodents and limited information in chronic hepatitis C with mild fibrosis.
The purpose of this study is to investigate the effect of long-term administration of oral Losartan, an AT1 receptor antagonist, on liver fibrogenesis in patients with chronic hepatitis C and fibrosis F2-F3 (METAVIR score).
Condition | Intervention | Phase |
---|---|---|
Chronic Hepatitis C Liver Fibrosis |
Drug: Losartan |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment |
Official Title: | Effect of Long-Term Administration of Oral Losartan on Hepatic Fibrogenesis and Gene Expression in Chronic Hepatitis C With Significant Liver Fibrosis. |
Ages Eligible for Study: | 35 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Principal Investigator: | Pere Ginès, M.D. | Liver Unit, Institut Clínic de Malalties Digestives, Hospital Clínic, Barcelona |
Study Chair: | Vicente Arroyo, M.D. | Liver Unit, Institut Clínic de Malalties Digestives, Hospital Clínic, Barcelona |
Study ID Numbers: | ARAHEPC, Protocol number: 02-0491 |
Study First Received: | March 2, 2006 |
Last Updated: | November 21, 2007 |
ClinicalTrials.gov Identifier: | NCT00298714 History of Changes |
Health Authority: | Spain: Spanish Agency of Medicines |
Hepatitis C, Chronic |
Liver Diseases Losartan Hepatitis, Chronic Hepatic Fibrosis Fibrosis Hepatitis, Viral, Human Cardiovascular Agents Liver Cirrhosis Angiotensin II |
Antihypertensive Agents Angiotensin II Type 1 Receptor Blockers Hepatitis Virus Diseases Digestive System Diseases Hepatitis C Anti-Arrhythmia Agents Hepatitis C, Chronic |
Losartan Liver Diseases RNA Virus Infections Molecular Mechanisms of Pharmacological Action Hepatitis, Chronic Flaviviridae Infections Fibrosis Hepatitis, Viral, Human Cardiovascular Agents Liver Cirrhosis Antihypertensive Agents |
Pharmacologic Actions Angiotensin II Type 1 Receptor Blockers Hepatitis Virus Diseases Pathologic Processes Digestive System Diseases Therapeutic Uses Anti-Arrhythmia Agents Hepatitis C Hepatitis C, Chronic |